V. Mullally

Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.

S. Dutta, T. Marbury, E. Lawitz, 2015, Journal of hepatology.

Compliance with RSV prophylaxis: Global physicians’ perspectives

A. Campbell, L. Fredrick, V. Mullally, 2009, Patient preference and adherence.

Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders

M. Kozal, M. Charafeddine, D. Cohen, 2019, Journal of medical virology.

1190 STUDY OF ABT-267 2-DAY MONOTHERAPY FOLLOWED BY 12-WEEK COMBINATION THERAPY IN TREATMENT-NAÏVE PATIENTS WITH CHRONIC HCV GENOTYPE 1 INFECTION

M. Epstein, T. Pilot‐Matias, T. Marbury, 2013 .